INTRODUCTION {#s1}
============

Breast cancer is one of the most common cancers occurring in women worldwide with 1.7 million new cases (25.2% of all cancers in women) and 0.5 million-cancer deaths (14.7% of all cancer death in women) according to an estimate from the International Agency for Research on Cancer (IARC) \[[@R1]\]. Breast cancer has been widely classified based on specific gene expression signature and receptor status. Based on PAM50 gene expression signature, breast cancer is categorized into six '\'intrinsic'' subtypes namely, Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like, and Normal-like \[[@R2], [@R3], [@R4]\], of which, Basal-like type has poor prognosis \[[@R5]\]. Based on receptor status, breast cancer is categorized into estrogen receptor (ER)-positive type, progesterone receptor (PgR)-positive type, HER2 positive type, and triple-negative type (ER-negative, PgR- negative, HER2-negative) (TNBC). Among them, TNBC has the poorest prognosis. Notably, among 70-80% of Basal-like type of breast cancer has been reported to fall into TNBC category \[[@R6]\].

Tumors are comprised of population of cancer cells and distinct cancer stem cells (CSCs), which are largely undifferentiated tumorigenic cells with stem-like properties such as self-renewal and multipotency \[[@R7], [@R8]\]. Most CSCs are resistant to conventional anti-tumor treatments, chemo- and radio-therapies, which consequently leads tumor recurrence and metastasis. Therefore, the development of targeted therapies against CSCs is highly required to improve poor clinical outcome.

CSCs in breast tumor patients can be identified based on the expression of aldehyde dehydrogenase (ALDH) isoforms. ALDH1 has been reported to be enriched in CSCs of several cancer types, including breast cancer and is a potential CSC marker \[[@R9], [@R10], [@R11]\]. Among ALDH1 gene family, isoforms *ALDH1A1* and *ALDH1A3* are also known as CSCs markers in several cancers \[[@R11], [@R12], [@R13], [@R14]\]. Particularly, isoform *ALDH1A3* has been reported to contribute significantly to ALDH1 activity in breast cancer cells and its expression significantly correlates with cancer type, tumor grade and metastasis in breast tumor patients \[[@R15]\]. On the other hand, there are controversial results regarding the involvement of ALDH1 in breast cancer subtypes \[[@R16], [@R17], [@R18]\].

c-Met is a receptor-type tyrosine kinase, which is involved in wide range of cellular responses such as proliferation, motility, migration, invasion and tumor angiogenesis \[[@R19], [@R20]\]. c-Met has been reported to be highly expressed and aberrantly activated in variety of cancers \[[@R21], [@R22], [@R23]\]. High expression of c-Met correlating with the expression of CSCs markers such as CD133, CD44, and ALDH1 has also been reported \[[@R24], [@R25], [@R26]\]. Furthermore, c-Met protein has been reported to be involved in biological processes of head and neck, and pancreatic CSCs \[[@R26], [@R27]\]. However, the relationship of c-Met with ALDH1 positive CSCs in breast cancer subtypes still remains unclear.

In this study, we show that high expression of c-Met correlates with the expression of *ALDH1A3* in breast cancer. Patients with co-expression of *c-Met* and *ALDH1A3* at tumor stage III-IV showed poor clinical outcome. Furthermore, c-Met inhibitors suppressed the viability and tumor-sphere formation of ALDH1^high^ cells. These results suggest that c-Met is essential for the viability and tumor formation of ALDH1 positive breast CSCs. Therefore, c-Met protein is a promising therapeutic target for ALDH1 positive breast CSCs.

RESULTS {#s2}
=======

Correlation of *c-Met* with CSC markers at gene expression level in human breast cancers {#s2_1}
----------------------------------------------------------------------------------------

To investigate the association of *c-Met* with CSC markers such as *ALDH1A1*, *ALDH1A3*, *CD44*, and *CD133* at gene expression levels in human breast cancers, we analyzed mRNA data and the clinical information of 1904 patients of breast cancers from cBioPortal for Cancer Genomics \[[@R28], [@R29]\]. As shown in Figure [1A](#F1){ref-type="fig"}, high expression of *c-Met* (MET^+^) correlated with expression of CSC markers, *ALDH1A1* (*p* \< 0.001), *ALDH1A3* (*p* \< 0.001), and *CD133* (*p* \< 0.001) in breast cancers. In addition, scatter plots analysis also indicated that *c-Met* expression correlated with *ALDH1A1* (*p* = 0.0077), *ALDH1A3* (*p* \< 0.001) and *CD133* expression (*p* \< 0.001) (Figure [1B](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). *c-Met* expression was also found to be associated with several undifferentiated markers, such as *KLF4*, *c-Myc*, *Notch1*, *Notch3*, and *BMI1* (Table [1](#T1){ref-type="table"}). Next we examined the mRNA expression level of *c-Met* in the specific breast cancer subtypes. As shown in Figure [1C](#F1){ref-type="fig"}, *c-Met* mRNA was found to be enriched in Basal-like type in comparison with other subtypes, such as Normal-like, Luminal A, Luminal B, HER2-enriched, and Claudin-low.

![*c-Met* expression correlates with gene expression of human breast CSC markers\
**A.** Gene expression levels of *ALDH1A1*, *ALDH1A3*, *CD44*, and *CD133* with high (c-Met^+^) and low (c-Met^-^) *c-Met* expression in primary breast tumors. Values are shown as box-and-whisker plot (Tukey\'s test, \*\**p* \< 0.01). **B**. Correlation of *c-Met* with *ALDH1A1*, *ALDH1A3*, *CD44*, and *CD133* in primary breast tumors. Values are shown as scattered plots. The coefficient of correlation (r) and the *p* value (*p*) are indicated. **C**. *c-Met* expression levels in breast cancer subtypes. Values are shown as box-and-whisker plot (Tukey\'s test, \*\**p* \< 0.01).](ganc-08-628-g001){#F1}

###### Correlation analysis between *c-Met* with cancer stem cell or undifferentiated markers in all stage, stage 0, I, II and stage III, IV of breast tumors

  mRNA co-expression MET vs.   ALL Stage   Stage I-II   Stage III-IV                     
  ---------------------------- ----------- ------------ -------------- --------- ------- ---------
  *ALDH1A1*                    0.06        0.008        0.05           0.058     -0.03   0.736
  *ALDH1A3*                    0.22        \<0.001      0.21           \<0.001   0.40    \<0.001
  *CD44*                       0.02        0.381        0.01           0.857     0.04    0.637
  *CD133*                      0.30        \<0.001      0.31           \<0.001   0.40    \<0.001
  *KLF4*                       0.10        \<0.001      0.11           \<0.001   0.12    0.181
  *MYC*                        0.14        \<0.001      0.15           \<0.001   0.17    0.055
  *NANOG*                      -0.04       0.064        -0.02          0.560     0.01    0.895
  *NOTCH1*                     0.17        \<0.001      0.16           \<0.001   0.43    \<0.001
  *NOTCH3*                     0.06        0.010        0.02           0.449     0.22    0.017
  *OCT4*                       0.02        0.325        0.00           0.888     0.35    \<0.001
  *SOX2*                       0.00        0.882        0.01           0.730     -0.05   0.609
  *STAT3*                      -0.03       0.156        -0.05          0.078     -0.05   0.558
  *BMI1*                       -0.16       \<0.001      -0.17          \<0.001   -0.20   0.023

Correlation of *c-Met* with *ALDH1A3* and *CD133* at gene expression level in breast cancer at tumor stage III-IV {#s2_2}
-----------------------------------------------------------------------------------------------------------------

Since overexpression of c-Met contributes to cancerous progression \[[@R21],[@R22],[@R23]\], we next examined *c-Met* expression at various tumor stages. Among early tumor stage lesions (0, I, II; *n* = 1279), 45% were c-Met^+^ (n = 573), contrary to 59% of c-Met^+^ (*n* = 74) at tumor late stage lesions (III, IV; *n* = 124). As c-Met^+^ tumor lesions were higher in tumor stage III-IV, in contrast with stage 0, I, and II, we next focused to analyze the relationship between *c-Met* gene expression and CSC markers in breast cancer subtypes at tumor stage III-IV. *c-Met* mRNA was found to be enriched in Basal-like type in comparison with other subtypes at stage III and IV (Figure [2A](#F2){ref-type="fig"}). As shown in Figure [2B](#F2){ref-type="fig"}, c-Met^+^ strongly correlated with ALDH1A3**^+^** (*p* \< 0.001). c-Met^+^ also weakly associated with CD133^+^ (*p* = 0.0025). Scatter plots analysis also indicated that *c-Met* expression correlated with *ALDH1A3* (*p* \< 0.001) and *CD133* expression (*p* \< 0.001) (Figure [2C](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}). *c-Met* expression was also found to be associated with several undifferentiated markers, such as *Notch1*, *Oct4*, and *BMI1* (Table [1](#T1){ref-type="table"}). These results indicate that c-Met plays important roles in ALDH1 and/or CD133 positive CSCs.

![Correlation of *c-Met* with *ALDH1A3* and *CD133* at gene expression level in tumor stage III and IV of breast cancer\
**A.** *c-Met* expression levels in breast cancer subtypes of tumor stage III-IV. Values are shown as box-and-whisker plot (Tukey\'s test, \*\**p* \< 0.01). **B**. Gene expression levels of *ALDH1A1*, *ALDH1A3*, *CD44*, and *CD133* with high (c-Met+) and low (c-Met -) *c-Met* expression at tumor stage III-IV. Values are shown as box-and-whisker plot (Tukey\'s test, \*\**p* \< 0.01). **C**. Correlation of *c-Met* with *ALDH1A1*, *ALDH1A3*, *CD44*, and *CD133* at tumor stage III-IV. Values are shown as scattered plots. The coefficient of correlation (r) and the *p* value (*p*) are indicated.](ganc-08-628-g002){#F2}

Co-expression of *c-Met*^high^ and *ALDH1A3*^high^ indicated poor prognosis {#s2_3}
---------------------------------------------------------------------------

Further, we next performed Kaplan-Meier analysis of *c-Met* and CSC markers at tumor stage III-IV. *c-Met*^high^ patients did not show poor prognosis (*p* = 0.11) (Figure [3A](#F3){ref-type="fig"}), whereas *ALDH1A3*^high^(*p* = 0.0049) and *CD133*^high^(*p* = 0.0088) showed poor prognosis (Figure [3B](#F3){ref-type="fig"}). Interestingly, co-expression of both *c-Met*^high^ with *ALDH1A3*^high^ (*p* = 0.0065), and with *CD133*^high^ (*p* = 0.0023) indicated poor prognosis (Figure [3C](#F3){ref-type="fig"}). These results indicate that c-Met plays important roles in cancerous progression and contributed to the poor prognosis in ALDH1 positive and/or CD133 positive breast CSCs. Since the role of c-Met in biological properties of CD133 positive CSCs is reported \[[@R24], [@R32], [@R33]\], hence, we focused on investigating the roles of c-Met in ALDH1 positive breast CSCs.

![Co-expression of *c-Met* with *ALDH1A3* or *CD133* contributes to poor prognosis in breast cancer patients at tumor stage III-IV\
Kaplan-Meier Survival curves of human breast cancer at tumor stage III-IV. **A**. *c-Met* expression. **B**. *ALDH1A1, ALDH1A3, CD44* or *CD133* expression. **C**. *c-Met* and *ALDH1A1*, *ALDH1A3*, *CD44* or *CD133* expression.](ganc-08-628-g003){#F3}

c-Met inhibitors suppressed viability of ALDH1 positive CSCs {#s2_4}
------------------------------------------------------------

To reveal the role of c-Met in CSCs, we used MDA-MB157 and MDA-MB468 cell lines derived from human Basal-like type of breast cancer. c-Met protein was found to be highly expressed in MDA-MB157 cells in contrast to MDA-MB468 cells (Figure [4A](#F4){ref-type="fig"}). Next, we examined the effects of nine c-Met inhibitors on the viability of MDA-MB157 cells expressing higher c-Met protein (Table [2](#T2){ref-type="table"}). Four c-Met inhibitors such as Crizotinib, Foretinib, PHA-665752 and Tivantinib strongly suppressed the viability of MDA-MB157 cells (Figure [4B](#F4){ref-type="fig"}). These results were consistent with the results of inhibition of c-Met phosphorylation level (indicating its activity) on treatment with c-Met inhibitors in MDA-MB157 cells (Figure [4C](#F4){ref-type="fig"}). Therefore, we next examined the inhibitory effects of these four c-Met inhibitors on the viability of ALDH1high cells derived from MDA-MB157 and MDA-MB468 cell lines. Isolated ALDH1^high^ cells derived from both MDA-MB157 and MDA-MB468 cell lines showed CSCs properties such as self-renewal, multi-differentiation, and tumorigenesis ([Supplementary Figure 2A and 2B](#SD1){ref-type="supplementary-material"}) as previously reported \[[@R9]\]. Interestingly, both c-Met and p-Met expression is higher in ALDH1^high^ cells than ALDH1^low^ cells (Figure [5A](#F5){ref-type="fig"}). The result suggests that ALDH1^high^ cells have high activity of c-Met. The c-Met inhibitors except for Tivantinib suppressed viability of ALDH1^high^ cells in both cell lines. The 50% cell growth inhibitory concentrations (IC~50~) of Crizotinib, Foretinib, and PHA-665752 were found to be lower in MDA-MB157 cells expressing higher c-Met protein than that in MDA-MB468 cells expressing lower c-Met protein (Figure [5B-D](#F5){ref-type="fig"}). Interestingly, Tivantinib specifically suppressed the viability of ALDH1^high^ MDA-MB157 cells. These results suggest that c-Met is necessary for the viability of ALDH1 positive breast CSCs.

![c-Met inhibitors suppressed cell viability and c-Met activation in Basal-like type of breast cancer cell lines\
**A.** c-Met expression in Basal-like type of breast cancer cell lines, MDA-MB157 and MDA-MB468 were analyzed by Immunoblot. β-actin was used as an internal control. **B**. Viability of MDA-MB157 cells after treatment with c-Met inhibitors (1, 10 and 100 μM) compared with 0.02% DMSO for 3 days was assessed by the amount of formazon formed by WST assay. Numerical values of test groups are shown with respect to 0.02% DMSO treated group. All data is represented as the mean ± S.D. of three independent experiments. **C**. c-Met phosphorylation level in MDA-MB157 was analyzed by immunoblot. MDA-MB157 cells were treated for 6h with Crizotinib (1.5 μM), Foretinib (1.5 μM), PHA-665752 (10 μM) and Tivantinib (0.5 μM).](ganc-08-628-g004){#F4}

###### List of c-Met inhibitors

  Compound name   Action mechanism                    Targets                                        Reference
  --------------- ----------------------------------- ---------------------------------------------- ---------------
  NVP-BVU972      ATP competitive Met inhibitor       c-Met                                          [@R43]
  Tivantinib      ATP non-competitive Met inhibitor   c-Met                                          [@R41],[@R42]
  BMS777607       ATP competitive Met inhibitor       c-Met, RON, Axl, TYRO3 and MER                 [@R44]
  AMG-208         ATP competitive Met inhibitor       c-Met and RON                                  [@R45]
  Cabozantinib    ATP competitive Met inhibitor       c-Met, VEGFR, RETKIT, FLT3 and TIE2            [@R46]
  Foretinib       ATP competitive Met inhibitor       c-Met, VEGFR, AXL, PDGFR, KIT, FLT3 and TIE2   [@R47],[@R48]
  PF-04217903     ATP competitive Met inhibitor       c-Met                                          [@R49],[@R50]
  Crizotinib      ATP competitive Met inhibitor       c-Met and ALK                                  [@R51],[@R52]
  PHA-665752      ATP competitive Met inhibitor       c-Met, RON, FLK1 and c-Abl                     [@R53],[@R54]

![c-Met inhibitors suppressed viability of ALDH1^high^ cells derived from Basal-like type of breast cancer cells lines\
**A.** c-Met and Phosphorylated c-Met (p-Met) expression in ALDH1^high^ or ALDH1^low^ cells from MDA-MB157 were analyzed by Immunoblot. β-actin was used as an internal control. **B.-C.** Cell viability based on formation of formazon product as assessed by the WST-1 assay after 3 days of treatment with c-Met inhibitors, Crizotinib, Foretinib, PHA-665752, and Tivantinib (0.03, 0.1, 0.3, 1, 3 and 10 μM) in ALDH1^high^ cells derived from MDA-MB157 (B) and MDA-MB468 (C). Numerical values of test groups are shown with respect to 0.02% DMSO treated group. **D.** *In vitro* IC~50~ values of c-Met inhibitors in ALDH1^high^ cells derived from MDA-MB 157 and MDA-MB 468. All data is represented as the mean± S.D. from three independent experiments.](ganc-08-628-g005){#F5}

c-Met inhibitors suppressed tumor-sphere formation of ALDH1 positive CSCs {#s2_5}
-------------------------------------------------------------------------

To investigate the role of c-Met in tumor formation of ALDH1 positive CSCs, we next examined the inhibitory effects of aforementioned inhibitory compounds on tumor-sphere formation in ALDH1 positive CSCs derived from MDA-MB157 *in vitro* system. As shown in Figure [6A and 6B](#F6){ref-type="fig"}, the inhibitory compounds were observed to suppress tumor-sphere formation. The IC~50~ values of these compounds for tumor-sphere formation were 0.18 μM (Crizotinib), 0.21 μM (Foretinib), 3.4μM (PHA-665752), and 0.18 μM (Tivantinib) (Figure [6C](#F6){ref-type="fig"}). These results suggest that c-Met is essential for tumor-sphere formation of ALDH1 positive CSCs in breast cancer cells.

![c-Met inhibitors suppressed tumor-sphere formation of ALDH1^high^ breast cancer cells\
**A.** Tumor-spheres of ALDH1^high^ cells derived from MDA-MB157 cells were incubated with c-Met inhibitors, Crizotinib (1 μM), Foretinib (1 μM), PHA-665752 (10 μM) and Tivantinib (1 μM) for 6 days. **B**. ATP level was assessed by the Cell-Titer Glo assay after treating tumor-spheres for 6 days with c-Met inhibitors, Crizotinib, Foretinib, Tivantinib (0.03, 0.1, 0.3, 1, and 3 μM) and PHA-665752 (0.6125, 1.25, 2.5, 5, and 10 μM). **C**. *In vitro* IC~50~ values with respect to decrease in ATP level on treatment with c-Met inhibitors. Numerical values of test groups are shown with respect to 0.02% DMSO treated group. All data is represented as the mean± S.D. from three independent experiments. Scale bar, 100 μm.](ganc-08-628-g006){#F6}

Taken together with aforementioned results, it can be inferred that c-Met is specifically essential for cell viability and tumor-sphere formation of ALDH1 positive human breast CSCs.

DISCUSSION {#s3}
==========

High expression of *c-Met* correlated with the expression of *ALDH1A3* in Basal-like type of breast cancer (Figure [1C](#F1){ref-type="fig"}). Since breast cancer stem cells exhibit a Basal-like phenotype \[[@R34]\], our result may thus provide new insights into the role of c-Met in ALDH1 positive CSCs of Basal-like type of breast cancer. It has been reported that knock-down of c-Met by siRNA and inhibitor treatment results in decrease of *ALDH1A3* gene expression and ALDEFLUOR activity in pancreatic cancer cell lines with high levels of c-Met \[[@R25]\]. Similarly, high c-Met expression and its activation are also suggested to be involved in the promotion of *ALDH1A3* gene expression in Basal-like type of breast cancer.

Several studies have reported that patients with higher expression of ALDH1 have poor prognosis in several cancers \[[@R9], [@R35]\]. In our study, Kaplan-Meier analysis revealed that patients with high *ALDH1A3* expression at tumor stage III-IV had poor outcome (*p* = 0.0049, Figure [3B](#F3){ref-type="fig"}). Similarly, patients expressing both *c-Met* and *ALDH1A3* at tumor stage III-IV had poor prognosis (*p* = 0.0065, Figure [3C](#F3){ref-type="fig"}). *c-Met* was found to be enriched in Basal-like type in comparison with other subtypes (Figure [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). However, patients expressing high *c-Met* and *ALDH1A3* in Basal-like type did not show poor outcome (*p* = 0.20; *n* = 199, [Supplementary Figure 1D](#SD1){ref-type="supplementary-material"}), which could be attributed to no correlation between *c-Met* and *ALDH1A3* in Basal-like type ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}, *p* = 0.58, r = 0.039). In spite of no correlation between *c-Met* and *ALDH1A3* expression, major population of Basal-like type patients expressed high expression of *c-Met* and *ALDH1A3* (*n* = 93 in 199). Therefore, c-Met may play an important role in cancerous progression in Basal-like type. On the other hands, at tumor stage III-IV, of total analyzed patient samples (*n* = 124), each subtypes were distributed as follows; Luminal A (23%, *n* = 28), Luminal B (28%, *n* = 35), HER2-enriched (17%, n = 21), Claudin-low (16%, *n* = 20), Normal-like (5%, *n* = 6), and Basal-like (11%, *n* = 14). Therefore, co-expression of both *c-Met* and *ALDH1A3* at late tumor stages may contribute to poor clinical outcome not only in Basal-like but also in other subtypes. Since efficacy of chemotherapy at cancer spreading stage III-IV is extremely crucial, targeting c-Met in ALDH1 positive breast CSC may possibly decrease the severity of metastatic breast cancer and hence may lead to the survival of breast cancer patients. In addition, previous studies reported that ALDH1 is required for maintaining a drug-resistant cell subpopulation of stomach and breast cancer cells \[[@R36], [@R37], [@R38], [@R39]\]. Therefore, considering this, the drug resistance characteristics of breast cancers expressing *c-Met* and *ALDH1A3* should be analyzed in detail in the future for targeted cancer therapy.

We found that c-Met inhibitors suppressed cell viability and tumor-sphere formation of ALDH1^high^ cells (Figure [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). ALDH1 enzyme catalyzes the oxidation of aldehydes into corresponding acetic acids, and is involved in detoxification of toxic aldehyde intermediates produced in cancer cells. Recent studies reported that ALDH1 decreases ROS levels in various cancer cells and metabolizes toxic aldehydes formed by lipid peroxidation generated from intracellular lipids due to ROS \[[@R36], [@R40]\]. Since we observed strong correlation between ALDH1 and c-Met, use of c-Met inhibitors in ALDH1^high^ cells may have accumulated ROS and toxic aldehydes, which consequently may have lead to the induction of apoptosis in cancer cells.

Thus, it is suggested that c-Met plays an important role in ALDH1 positive breast CSCs. Although the ALDH1^high^ cells derived from MDA-MB157 and MDA-MB468 cells have been cultured *in vitro* in the presence of FBS, no loss in CSCs properties was observed ([Supplementary Figure 2A and 2B](#SD1){ref-type="supplementary-material"}). Since, loss of stem cell property due to long term culture of cells in *in vitro* in the presence of FBS has been reported, hence appropriate measures should be taken for long term culture of CSCs.

Among c-Met inhibitors, Crizotinib, Foretinib, PHA-665752 and Tivantinib, only Tivantinib specifically suppressed viability of high c-Met expressing MDA-MB157 cells as compared to low c-Met expressing MDA-MB468 cells (Figure [5](#F5){ref-type="fig"}). These results may depend on the inhibitory mechanisms of Tivantinib against c-Met activity. The c-Met inhibitors except Tivantinib are ATP competitor that docks to active site of c-Met kinase. ATP competitors generally inhibit the activity of other kinases and function of ATP associated molecules. In fact, Crizotinib, Foretinib and PHA-665752 strongly suppress the cell viability by inhibition of other kinases and ATP associated molecules (Table [2](#T2){ref-type="table"}). On the other hand, Tivantinib, a non-ATP competitor, inhibits c-Met autophosphorylation and is highly selective for the inactive or non-phosphorylated form of c-Met by binding to ATP-binding cleft \[[@R41], [@R42]\]. Furthermore, the specific inhibitory effect of Tivantinib is profiled against 230 human kinases \[[@R41]\]. Non-ATP competitor such as Tivantinib binding to allosteric site must be explored further, as it may contribute to develop specific drugs targeting to c-Met in the future.

CONCLUSION {#s4}
==========

In this study, we showed that high expression of *c-Met* correlated with the expression of *ALDH1A3* in Basal-like type of breast cancer. Patients with co-expression of *c-Met* and *ALDH1A3* at tumor stage III-IV showed poor clinical outcome. Furthermore, c-Met inhibitors suppressed the cell viability and tumor-sphere formation of ALDH1^high^ cells. These results suggest that c-Met is essential for the viability and tumor formation of ALDH1 positive CSCs. Therefore, c-Met protein is potential therapeutic target for ALDH1 positive breast CSCs.

MATERIALS AND METHODS {#s5}
=====================

Cell culture {#s5_1}
------------

Human Basal-like type of breast cancer cell lines (MDA-MB157 and MDA-MB468) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cell lines were grown in Dulbecco\'s Modified Eagle Medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS) (Biosera, Dominican Republic) and penicillin/streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 95% air/5% CO~2~.

c-Met inhibitors and antibodies {#s5_2}
-------------------------------

c-Met inhibitors (AMG-208, BMS 777607, Cabozantinib, Crizotinib, Foretinib, NVP-BVU972, PF-04217903, PHA-665752, Tivantinib) were purchased from Namiki Inc. (Japan). All compounds dissolved in DMSO. Rabbit polyclonal c-Met antibody was purchased from Santa Cruz Inc. (USA). Rabbit monoclonal phospho-Met (Tyr1234/1235) antibody, HRP-conjugated anti-rabbit IgG and anti-mouse IgG were purchased from Cell Signaling Technology (USA). Mouse monoclonal β-actin antibody was obtained from Wako Inc. (Japan).

Flow cytometry {#s5_3}
--------------

Cells were exfoliated from culture dish by accutase (Innovative Cell Technology) and filtered through 40μm cell strainers (Greiner) to obtain single cells. The ALDH1^high^ cells were isolated from MDA-MB157 and MDA-MB468 cells by ALDEFLUOR assay kit (Stem Cell Technology) or AldeRed ALDH detection assay kit (MERCK) according to the manufacturer\'s instructions. Briefly, cells (2×10^6^) were incubated with the substrate for ALDH1 (5μL substrate/mL medium) for 30 min at 37°C. As a negative control for the ALDEFLUOR assay and AldeRed assay, cells were incubated with ALDH1 inhibitor, diethylaminobenzaldehyde (DEAB). The ALDH1^high^ cells were sorted by cell sorter (FACS AriaII, BD Bioscience) by taking the negative control into consideration. The analysis of CD10/EpCAM positive cells from MDA-MB157 and MDA-MB468 cells. Suspended MDA-MB468 cells (1×10^6^) were incubated with anti-CD10 (APC) (BD Bioscience) and anti-EpCAM (PE) (BD Bioscience) for 1hr on ice, after which the sample was washed with fresh FACS buffer (2%FBS in 1×PBS (-)). For this experiments, cells were analyzed using a FACS Calibur (BD Bioscience).

WST-8 assay {#s5_4}
-----------

Cells (3×10^5^/well) were seeded into 96 well culture plate (Sigma). One day post seeding, cells were treated with c-Met inhibitors for 3, 5, and 7 days. Cell viability was detected by WST-8 assay (Cell Counting Kit-8 (DOJINDO)). The formazan dye formed was measured by ARVO^TM^ MX (PerkinElmer) at 450 nm. Numerical values of test groups are shown with respect to 0.02% DMSO treated group.

Immunoblotting {#s5_5}
--------------

Cells were dissolved in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5 w/v% sodium deoxycholate, 0.1 w/v% SDS, 1.0 w/v% Nonidet P-40 and protease inhibitor cocktail (Thermo Fisher)). Eight μg of whole cell lysate proteins was electrophoresed by SDS-PAGE (8% gel) and transferred to Immobilon-P Transfer Membrane (Millipore) or Immobilon-FL Transfer Membrane (Millipore). The transferred membranes were then blocked with 5% BSA in TTBS (25 mM Tris (pH 7.5), 140 mM NaCl, 2.5 mM KCl and 0.1% Tween 20) and incubated with the primary antibodies. The membranes were then probed with the horseradish peroxidase-conjugated secondary antibody. Specific signals were detected by chemiluminescence reagent, such as Immunostar LD/Immunostar Basic (Wako) using ChemiDoc MP (Bio-Rad).

Tumor-sphere culture {#s5_6}
--------------------

Tumor-spheres were grown in DMEM culture medium containing 10% FBS, penicillin and streptomycin, 0.6% methyl cellulose (Wako), and 0.05 mM 2-mercaptoethanol (Sigma) at 37°C in a humidified atmosphere with 95% air/5% CO~2~. ALDH1^high^ cells (1x10^3^/well) were seeded and cultured in ultra low attachment 96-well plate (Greiner) for 6 days with or without inhibitory compounds. CellTiter-Glo^®^ luminescence assay (Promega) was performed by TR717 Micro plate Luminometer (TROPIX) using 96 well Micro-assay-plate (Greiner). Numerical values of test groups are shown with respect to 0.02% DMSO treated group.

Analysis of gene expression data {#s5_7}
--------------------------------

Gene expression data was analyzed using METABRIC, Nature 2012 & Nat. Commun. 2016 dataset deposited in cBioPortal \[[@R28], [@R29], [@R30], [@R31]\]. Clinical data of the breast cancer patients used in our present study are summarized in [Table S1](#SD1){ref-type="supplementary-material"}. The median age at diagnosis was 61.1 years (aged 21.9 to 96.3 years). The dataset contains mRNA expression data of 1,904 primary breast tumor samples (patients) with details of breast cancer subtype (Normal-like, *n* = 140; Luminal A, *n* = 679; Luminal B, *n* = 461; HER2-enriched, *n* = 220; Claudin-low, *n* = 199; Basal-like, *n* = 199; Not classified, *n* = 6). We retrieved the mRNA expression (Z-scores) of genes and evaluated co-expression of *c-Met* and several stem cell markers in either all or each of the tumor stage groups. We defined the *c-Met* expression as follows; all stage patients were divided into c-Met^+^(c-Met mRNA expression Z-score\>0, *n* = 837) and c-Met^-^(c-Met mRNA expression Z-score \< 0, *n* = 1067) in Figure [1A, 1C](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}. Tumor stage III and IV patients were classified into c-Met^+^(c-Met mRNA expression Z-score\>0, *n* = 74) and c-Met^-^(c-Met mRNA expression Z-score \< 0, *n* = 50) in Figure [2A, 2B](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}. Pearson\'s correlation coefficiency was calculated for these expression levels for the subtypes in Figure [1B](#F1){ref-type="fig"}, [2C](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}. We also compared *c-Met* expression in all or stage III-IV groups. Quantitative variables were analyzed by Tukey\'s test. Data with *p* value less than 0.05 were considered significant. Survival curves were plotted by the Kaplan-Meier method and compared by the Gehan-Breslow generalized Wilcoxon test using BellCurve for Excel ver2.11. "High" and "low" were defined as the upper top 40% and the lower 60% of Z-score respectively, in several genes at stages III-IV breast cancer patients. Follow-up period after diagnosis ranged from 5.8 to 274.3 months stages III-IV breast cancer patients.
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